|

Semaglutide Injectable Product Clinical Trials

4 actively recruiting trials across 1 location

Also known as: Ozempic

Pipeline

Phase 4: 2Phase 2/3: 1

Top Sponsors

  • University College Dublin1
  • Nordsjaellands Hospital1
  • Marzieh Salehi1
  • Jens D Hove, MD,PHD1

Indications

  • Weight Loss3
  • Obesity2
  • Heart Failure With Reduced Ejection Fraction1
  • HIV-1-infection1
  • Chronic Heart Failure1

Other3 trials

Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
Phase 4
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
Phase 2/3
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
N/A

San Antonio, Texas1 trial

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

University Health - Texas Diabetic Institute

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.